X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to fast-track the development of a vaccine candidate known as VTP-500 for the prevention of Middle East Respiratory Syndrome, the often fatal disease caused by the MERS coronavirus.
Lead Product(s): VTP-500
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-500
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Barinthus Biotherapeutics
Deal Size: $34.8 million Upfront Cash: Undisclosed
Deal Type: Partnership December 21, 2023
Details:
New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19, to accelerate epidemic and pandemic vaccine development. First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Recipient: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 30, 2023
Details:
The partnership aims to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox, caused by a member of the Orthopoxvirus viral family), an infectious disease that can lead to severe, life-threatening complications.
Lead Product(s): BNT166
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT166
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: BioNTech
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Partnership September 18, 2023
Details:
The partnership aims to advance the development of two vaccines candidates (one protein and one mRNA-based) using aVaxziPen’s solid dose vaccine-delivery platform, which could help end the need for frozen storage of vaccines, thereby improving equitable access to vaccines.
Lead Product(s): Protein-based Vaccine
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Recipient: aVaxziPen
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Partnership June 06, 2023
Details:
Application of the funding will be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the ‘Coronavirus X’ potential of VBI’s technology.
Lead Product(s): VBI-2900
Therapeutic Area: Infections and Infectious Diseases Product Name: VBI-2900
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Recipient: VBI Vaccines
Deal Size: $33.0 million Upfront Cash: Undisclosed
Deal Type: Partnership December 07, 2022
Details:
Under the agreement, SK bioscience will receive R&D expenses from CEPI. Initial funding will be made available to support phase 1/2 clinical trials of two mRNA vaccine platform projects.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: SK Bioscience
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 25, 2022
Details:
CEPI’s funding will support preclinical development and testing of Intravacc’s subunit vaccine candidate Avacc 101, which is based on its Outer Membrane Vesicle (OMV) platform.
Lead Product(s): Avacc 101
Therapeutic Area: Infections and Infectious Diseases Product Name: Avacc 101
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Intravacc
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Funding October 06, 2022
Details:
AFX3772, lead vaccine candidate targeting Streptococcus pneumoniae, developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) technology platform, is designed to elicit both B-cell and T-cell immune protection.
Lead Product(s): 24-Valent Pneumococcal Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: AFX3772
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Affinivax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
CEPI will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose.
Lead Product(s): UB-612
Therapeutic Area: Infections and Infectious Diseases Product Name: UB-612
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Vaxxinity
Deal Size: $9.3 million Upfront Cash: Undisclosed
Deal Type: Funding April 06, 2022
Details:
The collaborative program aims to establish preclinical proof of concept for a novel vaccine candidate designed to protect against new COVID-19 variants and that is also suitable for use in low- and middle-income countries.
Lead Product(s): Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Recipient: Affinivax
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Partnership December 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
